Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0

作者：

Liegeon, Geoffroy ^{[1
]}

Kaperak, Christopher ^{[1
]}

Friedman, Eleanor E. ^{[1
]}

Djuricich, Paul ^{[2
]}

Dawdani, Alicia ^{[1
]}

Stafford, Kane ^{[2
]}

Plotkin, Sophie ^{[1
]}

Schmitt, Jessica ^{[1
]}

Hazra, Aniruddha ^{[1
]}

Christopoulos, Katerina A. ^{[3
]}

Schneider, John A. ^{[1
]}

Mcnulty, Moira C. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Chicago, IL USA

[2] Univ Chicago, Dept Pharm, Chicago, IL USA

[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;

D O I：

10.1093/ofid/ofaf094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

引用

页数：7

共 50 条

[31] Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial
Murray, Miranda I.
Markowitz, Martin
Frank, Ian
Grant, Robert M.
Mayer, Kenneth H.
Hudson, Krischan J.
Stancil, Britt S.
Ford, Susan L.
Patel, Parul
Rinehart, Alex R.
Spreen, William R.
Margolis, David A.
HIV CLINICAL TRIALS, 2018, 19 (04): : 129 - 138
[32] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Santiago Moreno
Antonio Rivero
Pere Ventayol
Vicenç Falcó
Miguel Torralba
Melanie Schroeder
Victoria Neches
Laura Amanda Vallejo-Aparicio
Isaac Mackenzie
Matthew Turner
Cale Harrison
Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
[33] Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice
Borghetti, Alberto
Farinacci, Damiano
Ciccullo, Arturo
Dusina, Alex
Moschese, Davide
Iannone, Valentina
D'Angelillo, Anna
Lombardi, Francesca
Delle Donne, Valentina
Massaroni, Valentina
Visconti, Elena
Tamburrini, Enrica
Di Giambenedetto, Simona
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4970 - 4974
[34] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
Michael G. Sension
Laurence Brunet
Ricky K. Hsu
Jennifer S. Fusco
Quateka Cochran
Christine Uranaka
Gayathri Sridhar
Vani Vannappagari
Jean Van Wyk
Lewis McCurdy
Michael B. Wohlfeiler
Gregory P. Fusco
Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
[35] Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
Swindells, Susan
Lutz, Thomas
Van Zyl, Lelanie
Porteiro, Norma
Stoll, Matthias
Mitha, Essack
Shon, Alyssa
Benn, Paul
Huang, Jenny O.
Harrington, Conn M.
Hove, Kai
Ford, Susan L.
Talarico, Christine L.
Chounta, Vasiliki
Crauwels, Herta
Van Solingen-Ristea, Rodica
Vanveggel, Simon
Margolis, David A.
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
AIDS, 2022, 36 (02) : 185 - 194
[36] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Mills, Anthony
Richmond, Gary J.
Newman, Cheryl
Osiyemi, Olayemi
Cade, Jerry
Brinson, Cynthia
De Vente, Jerome
Margolis, David A.
Sutton, Kenneth C.
Wilches, Viviana
Hatch, Sarah
Roberts, Jeremy
McCoig, Cynthia
Garris, Cindy
Vandermeulen, Kati
Spreen, William R.
AIDS, 2022, 36 (02) : 195 - 203
[37] Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Engelman, Kathleen D.
Engelman, Alan N.
BIOCHEMISTRY, 2021, 60 (22) : 1731 - 1740
[38] Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine
Boateng, William K. B.
Carlin, Neil
Spira, Etan
Szabela, Maria E.
Ezeh, Kosisochukwu J.
ACG CASE REPORTS JOURNAL, 2025, 12 (01)
[39] Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
Gutner, Cassidy A.
Hocqueloux, Laurent
Jonsson-Oldenbuettel, Celia
Vandekerckhove, Linos
van Welzen, Berend J.
Slama, Laurence
Crusells-Canales, Maria
Sierra, Julian Olalla
DeMoor, Rebecca
Scherzer, Jenny
Ait-Khaled, Mounir
Bontempo, Gilda
Gill, Martin
Patel, Natasha
D'Amico, Ronald
Hove, Kai
Baugh, Bryan
Barnes, Nicola
Hadi, Monica
Low, Emma L.
Anand, Savita Bakhshi
Hamilton, Alison
Garges, Harmony P.
Czarnogorski, Maggie
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (07)
[40] Cabotegravir plus Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
Sension, Michael G.
Brunet, Laurence
Hsu, Ricky K.
Fusco, Jennifer S.
Cochran, Quateka
Uranaka, Christine
Sridhar, Gayathri
Vannappagari, Vani
Van Wyk, Jean
Mccurdy, Lewis
Wohlfeiler, Michael B.
Fusco, Gregory P.
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2709 - 2724

← 1 2 3 4 5 →